TRIM67 drives tumorigenesis in oligodendrogliomas through Rho GTPase-dependent membrane blebbing

Area of Science:

• Neuro-oncology
• Cancer biology
• Molecular genetics

Background:

• IDH mutant gliomas are classified as astrocytomas or oligodendrogliomas based on 1p/19q codeletion.
• Genomic alterations in IDH mutant gliomas are known, but transcriptional differences remain unclear.
• Tripartite Motif Containing 67 (TRIM67), an E3 ubiquitin ligase, is identified as a key oncogene in oligodendrogliomas.

Purpose of the Study:

• To investigate the role of Tripartite Motif Containing 67 (TRIM67) in oligodendroglioma pathogenesis.
• To elucidate the molecular mechanisms by which TRIM67 influences glioma cell behavior and tumor progression.

Main Methods:

• Utilized patient-derived oligodendroglioma tumorspheres for knockdown and overexpression studies of TRIM67.
• Employed high-throughput assays including RNA sequencing, mass spectrometry (MS), and coimmunoprecipitation (co-IP)-MS.
• Functional assays included immunofluorescence (IF), co-IP, and western blotting (WB); orthotopic implantation in mice assessed in vivo effects.

Main Results:

• TRIM67 overexpression altered cytoskeletal protein abundance and induced membrane blebbing.
• TRIM67-induced blebbing was mediated by NOGO-A/Rho GTPase/ROCK2 signaling and reversed by ROCK inhibitors.
• TRIM67 enhanced cell motility, reduced cell adherence, accelerated tumor growth, and decreased survival in vivo.

Conclusions:

• Upregulated TRIM67 drives oligodendroglioma pathogenesis by inducing blebbing-based rounded cell morphology.
• The mechanism involves Rho GTPase/ROCK-mediated signaling, impacting glioma cell behavior and tumor progression.